Cisplatin News and Research

RSS

Aligned approach to advanced bladder cancer treatment very much needed, study says

New study, involving eight Italian research centres, concluded that an aligned approach to the treatment of advanced bladder cancer is much needed, while confirming previously published results on survival estimates of associated salvage therapies.

18 Nov 2013

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

Alain C. Mita, MD, is fighting an uphill battle against small cell lung cancer. Despite the severity of the disease, the standard-of-care treatment remains the same today as it was nearly 30 years ago.

14 Nov 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Active ingredient of ipecac syrup inhibits growth of cancer cells

An old home remedy called ipecac syrup, once stocked in medicine cabinets in case of accidental poisoning, is showing promise as a new chemotherapy drug for bladder cancer.

4 Oct 2013

New agreement to expand scope of research project to evaluate MCT-485 for primary liver cancer

MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.

2 Oct 2013

Study: Antidepressant drugs prove to be effective against SCLC patients

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

27 Sep 2013

Cisplatin plus radiotherapy and HDRB proves beneficial in stage IIIB cervical cancer

Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

24 Sep 2013

Ferritin protects kidneys against damage by controlling iron

A protein, ferritin, protects kidneys against a damaging after-effect of injury, heart failure or hardened arteries by controlling levels of iron, according to a study published today by researchers at the University of Alabama at Birmingham in the Journal of Clinical Investigation.

10 Sep 2013

Study shows benefit of chemotherapy on survival of elderly patients with SCLC

Although numerous randomized clinical trials have demonstrated a benefit of chemotherapy for patients with small-cell lung cancer (SCLC), these trials have predominantly compared different chemotherapy regimens rather than comparing chemotherapy to best supportive care. Some of them included chest radiation or prophylactic cranial irradiation. Moreover, many trials excluded elderly patients.

5 Sep 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.

9 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Supporting cells in the inner ear can help repair damaged sensory hair cells, say researchers

Researchers have found in mice that supporting cells in the inner ear, once thought to serve only a structural role, can actively help repair damaged sensory hair cells, the functional cells that turn vibrations into the electrical signals that the brain recognizes as sound.

26 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2.

19 Jun 2013